IDEAS home Printed from https://ideas.repec.org/a/eee/respol/v53y2024i2s0048733323002226.html
   My bibliography  Save this article

The interdependent influence of lobbying and intellectual capital on new drug development

Author

Listed:
  • Van De Vrande, Vareska
  • Subramanian, Annapoornima M.
  • Lévesque, Moren
  • Klopf, Patricia

Abstract

Pharmaceutical firms are top lobbying spenders in the United States (US). While the potential benefits of lobbying are recognized in the literature, the criticism against unethical aspects of lobbying warrants pharmaceutical firms to strategize their lobbying activities. Our study addresses the question “How does a pharmaceutical firm's resource allocation decision toward lobbying activities (and other non-market activities) influence that firm's new drug launches and do these non-market activities interact with market activities?” Specifically, we investigate the interaction between lobbying and the intellectual capital (human, structural, and social capital) of firms. We use a formal model to develop our hypotheses, which we test on a sample of the largest US-listed pharmaceutical firms between 1999 and 2021. Our analyses suggest that human and structural capital weaken the effect of lobbying on the firm's rate of new drug launches, whereas a firm's social capital strengthens the relationship between lobbying and the rate of new drug launches.

Suggested Citation

  • Van De Vrande, Vareska & Subramanian, Annapoornima M. & Lévesque, Moren & Klopf, Patricia, 2024. "The interdependent influence of lobbying and intellectual capital on new drug development," Research Policy, Elsevier, vol. 53(2).
    • Handle: RePEc:eee:respol:v:53:y:2024:i:2:s0048733323002226
    DOI: 10.1016/j.respol.2023.104938
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0048733323002226
    Download Restriction: Full text for ScienceDirect subscribers only
    File URL: https://libkey.io/10.1016/j.respol.2023.104938?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Graddy-Reed, Alexandra, 2020. "Getting ahead in the race for a cure: How nonprofits are financing biomedical R&D," Research Policy, Elsevier, vol. 49(8).
    2. David Roodman, 2009. "How to do xtabond2: An introduction to difference and system GMM in Stata," Stata Journal, StataCorp LP, vol. 9(1), pages 86-136, March.
    3. Seong-Jin Choi & Nan Jia & Jiangyong Lu, 2015. "The Structure of Political Institutions and Effectiveness of Corporate Political Lobbying," Organization Science, INFORMS, vol. 26(1), pages 158-179, February.
    4. Zheng, Weiting & Ang, Siah Hwee & Singh, Kulwant, 2022. "The interface of market and nonmarket strategies: Political ties and strategic competitive actions," Journal of World Business, Elsevier, vol. 57(4).
    5. Kim Jin-Hyuk, 2008. "Corporate Lobbying Revisited," Business and Politics, De Gruyter, vol. 10(2), pages 1-25, September.
    6. Gopesh Anand & John Gray & Enno Siemsen, 2012. "Decay, Shock, and Renewal: Operational Routines and Process Entropy in the Pharmaceutical Industry," Organization Science, INFORMS, vol. 23(6), pages 1700-1716, December.
    7. Stephan, Paula E & Everhart, Stephen S, 1998. "The Changing Rewards to Science: The Case of Biotechnology," Small Business Economics, Springer, vol. 10(2), pages 141-151, March.
    8. Perkmann, Markus & King, Zella & Pavelin, Stephen, 2011. "Engaging excellence? Effects of faculty quality on university engagement with industry," Research Policy, Elsevier, vol. 40(4), pages 539-552, May.
    9. Rita Gunther McGrath & Atul Nerkar, 2004. "Real options reasoning and a new look at the R&D investment strategies of pharmaceutical firms," Strategic Management Journal, Wiley Blackwell, vol. 25(1), pages 1-21, January.
    10. Ivan Lugovoi & Dimitrios A. Andritsos & Claire Senot, 2022. "Novelty and scope of process innovation: The role of related and unrelated manufacturing experience," Production and Operations Management, Production and Operations Management Society, vol. 31(10), pages 3877-3895, October.
    11. Gimmon, Eli & Levie, Jonathan, 2010. "Founder's human capital, external investment, and the survival of new high-technology ventures," Research Policy, Elsevier, vol. 39(9), pages 1214-1226, November.
    12. Julia Porter Liebeskind & Amalya Lumerman Oliver & Lynne Zucker & Marilynn Brewer, 1996. "Social networks, Learning, and Flexibility: Sourcing Scientific Knowledge in New Biotechnology Firms," Organization Science, INFORMS, vol. 7(4), pages 428-443, August.
    13. Unsal, Omer, 2020. "Two faces of corporate lobbying: Evidence from the pharmaceutical industry," The North American Journal of Economics and Finance, Elsevier, vol. 51(C).
    14. Jin Hyung Kim, 2019. "Is your playing field unleveled? U.S. defense contracts and foreign firm lobbying," Strategic Management Journal, Wiley Blackwell, vol. 40(12), pages 1911-1937, December.
    15. Rod Shrader & Donald S. Siegel, 2007. "Assessing the Relationship between Human Capital and Firm Performance: Evidence from Technology–Based New Ventures," Entrepreneurship Theory and Practice, , vol. 31(6), pages 893-908, November.
    16. Rothaermel, Frank T., 2001. "Complementary assets, strategic alliances, and the incumbent's advantage: an empirical study of industry and firm effects in the biopharmaceutical industry," Research Policy, Elsevier, vol. 30(8), pages 1235-1251, October.
    17. Mark A. Youndt & Mohan Subramaniam & Scott A. Snell, 2004. "Intellectual Capital Profiles: An Examination of Investments and Returns," Journal of Management Studies, Wiley Blackwell, vol. 41(2), pages 335-361, March.
    18. Julie Juan Li & Kevin Zheng Zhou & Alan T Shao, 2009. "Competitive position, managerial ties, and profitability of foreign firms in China: an interactive perspective," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 40(2), pages 339-352, February.
    19. Jordi Blanes i Vidal & Mirko Draca & Christian Fons-Rosen, 2012. "Revolving Door Lobbyists," American Economic Review, American Economic Association, vol. 102(7), pages 3731-3748, December.
    20. Kiviet, Jan F., 1995. "On bias, inconsistency, and efficiency of various estimators in dynamic panel data models," Journal of Econometrics, Elsevier, vol. 68(1), pages 53-78, July.
    21. John Hagedoorn & Geert Duysters, 2002. "External Sources of Innovative Capabilities: The Preferences for Strategic Alliances or Mergers and Acquisitions," Journal of Management Studies, Wiley Blackwell, vol. 39(2), pages 167-188, March.
    22. Hui Chen & David Parsley & Ya-Wen Yang, 2015. "Corporate Lobbying and Firm Performance," Journal of Business Finance & Accounting, Wiley Blackwell, vol. 42(3-4), pages 444-481, April.
    23. Milgrom, Paul & Roberts, John, 1995. "Complementarities and fit strategy, structure, and organizational change in manufacturing," Journal of Accounting and Economics, Elsevier, vol. 19(2-3), pages 179-208, April.
    24. Wouters, Olivier J., 2020. "Lobbying expenditures and campaign contributions by the pharmaceutical and health-product industry in the United States, 1999- 2018," LSE Research Online Documents on Economics 103689, London School of Economics and Political Science, LSE Library.
    25. Matthew D. Hill & G. Wayne Kelly & G. Brandon Lockhart & Robert A. Ness, 2013. "Determinants and Effects of Corporate Lobbying," Financial Management, Financial Management Association International, vol. 42(4), pages 931-957, December.
    26. Usero, Belén & Fernández, Zulima, 2009. "First come, first served: How market and non-market actions influence pioneer market share," Journal of Business Research, Elsevier, vol. 62(11), pages 1139-1145, November.
    27. Karam Kang, 2016. "Policy Influence and Private Returns from Lobbying in the Energy Sector," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 83(1), pages 269-305.
    28. Rebecca R. Kehoe & Daniel Tzabbar, 2015. "Lighting the way or stealing the shine? An examination of the duality in star scientists' effects on firm innovative performance," Strategic Management Journal, Wiley Blackwell, vol. 36(5), pages 709-727, May.
    29. Richard Borghesi & Kiyoung Chang, 2015. "The determinants of effective corporate lobbying," Journal of Economics and Finance, Springer;Academy of Economics and Finance, vol. 39(3), pages 606-624, July.
    30. John Hagedoorn & Jos Schakenraad, 1994. "The effect of strategic technology alliances on company performance," Strategic Management Journal, Wiley Blackwell, vol. 15(4), pages 291-309, May.
    31. Kim, Jin-Hyuk, 2008. "Corporate Lobbying Revisited," Business and Politics, Cambridge University Press, vol. 10(2), pages 1-23, August.
    32. Benjamin Barber & Luis Diestre, 2019. "Pushing for speed or scope? Pharmaceutical lobbying and Food and Drug Administration drug review," Strategic Management Journal, Wiley Blackwell, vol. 40(8), pages 1194-1218, August.
    33. Jason Owen-Smith & Walter W. Powell, 2004. "Knowledge Networks as Channels and Conduits: The Effects of Spillovers in the Boston Biotechnology Community," Organization Science, INFORMS, vol. 15(1), pages 5-21, February.
    34. Arora, Ashish & Gambardella, Alfonso, 1990. "Complementarity and External Linkages: The Strategies of the Large Firms in Biotechnology," Journal of Industrial Economics, Wiley Blackwell, vol. 38(4), pages 361-379, June.
    35. Manuel Arellano & Stephen Bond, 1991. "Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment Equations," The Review of Economic Studies, Review of Economic Studies Ltd, vol. 58(2), pages 277-297.
    36. Pei Sun & Kamel Mellahi & Eric Thun, 2010. "The dynamic value of MNE political embeddedness: The case of the Chinese automobile industry," Journal of International Business Studies, Palgrave Macmillan;Academy of International Business, vol. 41(7), pages 1161-1182, September.
    37. Lee, Jeoung Yul & Jiménez, Alfredo & Choi, Seong-jin & Choi, Yun Hyeong, 2022. "Ideological polarization and corporate lobbying activity: The contingent impact of corruption distance," Journal of Business Research, Elsevier, vol. 141(C), pages 448-461.
    38. Zucker, Lynne G & Darby, Michael R & Brewer, Marilynn B, 1998. "Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises," American Economic Review, American Economic Association, vol. 88(1), pages 290-306, March.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Kolympiris, Christos & Kalaitzandonakes, Nicholas & Miller, Douglas, 2014. "Public funds and local biotechnology firm creation," Research Policy, Elsevier, vol. 43(1), pages 121-137.
    2. Unsal, Omer & Hassan, M. Kabir & Zirek, Duygu, 2016. "Corporate lobbying, CEO political ideology and firm performance," Journal of Corporate Finance, Elsevier, vol. 38(C), pages 126-149.
    3. Gammeltoft, Peter & Panibratov, Andrei, 2024. "Emerging market multinationals and the politics of internationalization," International Business Review, Elsevier, vol. 33(3).
    4. Woon Leong Lin, 2018. "Do Firm’s Organisational Slacks Influence the Relationship between Corporate Lobbying and Corporate Financial Performance? More Is Not Always Better," IJFS, MDPI, vol. 7(1), pages 1-23, December.
    5. Wei-Fong Pan, 2023. "Does a firm’s lobbying activity respond to its peers’ lobbying activity?," Public Choice, Springer, vol. 194(3), pages 297-324, March.
    6. Frank T. Rothaermel & Andrew M. Hess, 2007. "Building Dynamic Capabilities: Innovation Driven by Individual-, Firm-, and Network-Level Effects," Organization Science, INFORMS, vol. 18(6), pages 898-921, December.
    7. Verdiana Giannetti & Raji Srinivasan, 2022. "Corporate lobbying and product recalls: an investigation in the U.S. medical device industry," Journal of the Academy of Marketing Science, Springer, vol. 50(5), pages 941-960, September.
    8. Minnick, Kristina & Noga, Tracy, 2017. "The influence of firm and industry political spending on tax management among S&P 500 firms," Journal of Corporate Finance, Elsevier, vol. 44(C), pages 233-254.
    9. Serafinelli, Michel, 2013. "Good Firms, Worker Flows and Productivity," MPRA Paper 49055, University Library of Munich, Germany, revised 12 Aug 2013.
    10. Matthew McCarten & Ivan Diaz‐Rainey & Helen Roberts & Eric K. M. Tan, 2022. "Political connections, tacit power and corporate misconduct," Journal of Business Finance & Accounting, Wiley Blackwell, vol. 49(9-10), pages 1530-1552, October.
    11. Jun Hou & Pierre Mohnen, 2013. "Complementarity between In-house R&D and Technology Purchasing: Evidence from Chinese Manufacturing Firms," Oxford Development Studies, Taylor & Francis Journals, vol. 41(3), pages 343-371, September.
    12. Unsal, Omer, 2020. "Two faces of corporate lobbying: Evidence from the pharmaceutical industry," The North American Journal of Economics and Finance, Elsevier, vol. 51(C).
    13. Hassan, Mohammad Kabir & Unsal, Omer & Hippler, William J., 2020. "Financial industry lobbying and shareholder litigation outcomes: implications for managers and regulators," Research in International Business and Finance, Elsevier, vol. 53(C).
    14. Ghouma, Hatem H. & Hewitt, Carissa S., 2019. "Lobbying expenditures and sin stock market performance," Research in International Business and Finance, Elsevier, vol. 49(C), pages 176-190.
    15. Samargandi, Nahla & Fidrmuc, Jan & Ghosh, Sugata, 2015. "Is the Relationship Between Financial Development and Economic Growth Monotonic? Evidence from a Sample of Middle-Income Countries," World Development, Elsevier, vol. 68(C), pages 66-81.
    16. Lamar Crombach & Frank Bohn, 2024. "Uninformed voters with (im)precise expectations: Explaining political budget cycle puzzles," Economics and Politics, Wiley Blackwell, vol. 36(1), pages 275-311, March.
    17. Swan, Jacky & Goussevskaia, Anna & Newell, Sue & Robertson, Maxine & Bresnen, Mike & Obembe, Ademola, 2007. "Modes of organizing biomedical innovation in the UK and US and the role of integrative and relational capabilities," Research Policy, Elsevier, vol. 36(4), pages 529-547, May.
    18. Carter, Patrick, 2017. "Aid econometrics: Lessons from a stochastic growth model," Journal of International Money and Finance, Elsevier, vol. 77(C), pages 216-232.
    19. Dilla, Diana, 2017. "Staatsverschuldung und Verschuldungsmentalität [Public Debt and Debt Mentality]," MPRA Paper 79432, University Library of Munich, Germany.
    20. Massimo Filippini & Bettina Hirl & Giuliano Masiero, 2015. "Rational habits in residential electricity demand," IdEP Economic Papers 1506, USI Università della Svizzera italiana.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:53:y:2024:i:2:s0048733323002226. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu (email available below). General contact details of provider: http://www.elsevier.com/locate/respol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.